Alan Korman

Summary

Affiliation: Medarex Inc
Country: USA

Publications

  1. ncbi request reprint Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies
    Alan Korman
    Medarex Inc, 521 Cottonwood Drive, Milpitas, CA 95035, USA
    Curr Opin Investig Drugs 6:582-91. 2005
  2. ncbi request reprint Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques
    Tibor Keler
    Department of Preclinical Development, Medarex, Bloomsbury, NJ 08804, USA
    J Immunol 171:6251-9. 2003
  3. pmc Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
    F Stephen Hodi
    Department of Adult Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 100:4712-7. 2003
  4. pmc Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
    F Stephen Hodi
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 105:3005-10. 2008

Detail Information

Publications4

  1. ncbi request reprint Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies
    Alan Korman
    Medarex Inc, 521 Cottonwood Drive, Milpitas, CA 95035, USA
    Curr Opin Investig Drugs 6:582-91. 2005
    ..These events usually respond readily to short-term anti-inflammatory treatment and cessation of drug treatment, and even when suppressed in this manner appear to correlate with clinically significant and durable antitumor responses...
  2. ncbi request reprint Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques
    Tibor Keler
    Department of Preclinical Development, Medarex, Bloomsbury, NJ 08804, USA
    J Immunol 171:6251-9. 2003
    ..Repeated dosing of the 10D1 did not elicit monkey anti-human Ab responses in the monkeys. These observations support the development of CTLA-4 blockade for human immunotherapy...
  3. pmc Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
    F Stephen Hodi
    Department of Adult Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 100:4712-7. 2003
    ..These findings suggest that CTLA-4 antibody blockade increases tumor immunity in some previously vaccinated cancer patients...
  4. pmc Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
    F Stephen Hodi
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 105:3005-10. 2008
    ....